Seek Returns

ASND vs. BBIO: Ascendis Pharma vs. BridgeBio Pharma Stock Comparison

How do Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
Profile ItemASNDBBIO
NameAscendis Pharma A/SBridgeBio Pharma Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization16.90 billion USD14.47 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 28, 2015June 27, 2019
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ASND
BBIO
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Total Return (1Y)29.46%22.70%
Total Return (3Y, Annualized)40.62%40.97%
Total Return (5Y, Annualized)10.03%8.25%

Risk Profile

Drawdown History

ASND
BBIO
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Volatility (1Y, Annualized)38.62%44.39%
Beta (5Y)0.380.93
Max Drawdown (5Y)-55.93%-89.79%
Avg. Volume (3M)698.39K2.68M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ASND and BBIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Sharpe Ratio (1Y)0.650.41
Sortino Ratio (1Y)0.990.63

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Ascendis Pharma (ASND) earns 118.78% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

118.78%

ASND
118.78%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): BBIO does not report ROE, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Ascendis Pharma (ASND) reports 70.85%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

70.85%

ASND
70.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

64.98%

Max
83.12%
ASND
64.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
ROE (TTM)118.78%--
ROA (TTM)9.58%-13.97%
Net Margin (TTM)70.85%-59.84%
Operating Margin (TTM)64.98%-3.30%
Gross Margin (TTM)91.30%94.34%

Growth

Revenue Growth

Both Ascendis Pharma (ASND) at 98.03% and BridgeBio Pharma (BBIO) at 126.26% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.

Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Ascendis Pharma (ASND) nor BridgeBio Pharma (BBIO) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Revenue Growth (YoY)98.03%126.26%
Revenue Growth (3Y CAGR)141.43%86.30%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max
25.13
Q3
12.13
Median
5.52
ASND
2.99
Q1
2.47
Min
0.10

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Ascendis Pharma (ASND) carries debt-to-equity ratio of 0.31 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
ASND
0.31
Median
0.15
Q1
0.02
Min
0.00

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): BBIO does not report debt-to-equity ratio, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Current Ratio (MRQ)2.992.09
Debt / Equity (MRQ)0.31--
Net Debt / EBITDA-1.37--

Dividends

Dividend Yield (TTM)

Neither Ascendis Pharma (ASND) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Ascendis Pharma (ASND) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.68

Max
85.34
Q3
43.46
Median
26.69
ASND
19.68
Q1
13.30
Min
0.07

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): BBIO does not report P/E ratio, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.14

Max
58.18
Q3
25.77
ASND
16.14
Median
7.30
Q1
3.01
Min
0.01

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Ascendis Pharma (ASND) reports 10.45, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.45

Max
13.53
ASND
10.45
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59
Loading chart…
Ascendis Pharma (ASND) vs. BridgeBio Pharma (BBIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Ascendis Pharma (ASND) and BridgeBio Pharma (BBIO)
MetricASNDBBIO
P/E Ratio (TTM)19.68--
P/S Ratio (TTM)16.1415.31
P/B Ratio (MRQ)10.45-5.59
Free Cash Flow Yield (TTM)0.08%-1.98%